The underlying genetic mechanisms and early pathological events of children with primary cardiomyopathy (CMP) are insufficiently characterized. In this study, we aimed to Jirko Kühnisch and Christopher Herbst contributed equally to the work.
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The peer review history for this article is available at https://publons.com/publon/10. 1111/cge.13645. characterize the mutational spectrum of primary CMP in a large cohort of patients ≤18 years referred to a tertiary center. Eighty unrelated index patients with pediatric primary CMP underwent genetic testing with a panel-based next-generation sequencing approach of 89 genes. At least one pathogenic or probably pathogenic variant was identified in 30/80 (38%) index patients. In all CMP subgroups, patients carried most frequently variants of interest in sarcomere genes suggesting them as a major contributor in pediatric primary CMP. In MYH7, MYBPC3, and TNNI3, we identified 18 pathogenic/probably pathogenic variants (MYH7 n = 7, MYBPC3 n = 6, TNNI3 n = 5, including one homozygous (TNNI3 c.24+2T>A) truncating variant. Protein and transcript level analysis on heart biopsies from individuals with homozygous mutation of TNNI3 revealed that the TNNI3 protein is absent and associated with upregulation of the fetal isoform TNNI1. The present study further supports the clinical importance of sarcomeric mutation-not only in adultbut also in pediatric primary CMP. TNNI3 is the third most important disease gene in this cohort and complete loss of TNNI3 leads to severe pediatric CMP. recent studies lead to the identification of pathogenic variants in 26% to 39% of pediatric patients. 1, 2 These genetic defects exhibit variable expressivity and variable penetrance. Mutations in genes encoding components of the sarcomere and related binding proteins, Z-band, nuclear membrane, desmosomal, mitochondrial, and calcium handling proteins have all been found in children with CMP. 3 Only now, NGS techniques and genetic variant interpretation guidelines enable to unravel the genetic background in a reasonable percentage of primary CMP in children more systematically. We assembled a cohort of pediatric primary CMP patients and present their clinical phenotypes as well as spectrum of genetic variants. We present the distribution of genetic variants in certain functional groups and highlight genetic variants which can lead to severe CMP. In clinical practice, pediatric patients with mutation of Troponin I require special attention.
| MATERIAL AND METHODS

| Clinical evaluation
Unrelated patients with CMP were recruited at the Charité -Universitätsmedizin Berlin and the German Heart Center Berlin, Berlin, Germany between November 2011 and February 2017 (study design: Figure S1 ). Written informed consent was obtained from each subject or their legal guardians according to the Declaration of Helsinki.
The study was approved by the local institutional review board (ID EA2/083/13, EA2/131/10, Charité -Universitätsmedizin Berlin).
Probands ≤18 years and available family members were evaluated by medical history, physical examination, 12-lead electrocardiography, and transthoracic echocardiography. For patients recruited after heart transplantation (HTX), the clinical and echocardiographic data were collected by retrospective review of patients' records. Patients with a primary diagnosis of HCM, DCM, RCM, LVNC, or ARVC were included in the study. 4, 5 Patients who had secondary CMP (syndromic, neuromuscular, metabolic, or myocarditis) or CMP in combination with a structural congenital heart defect were excluded. ARVC was not included in the analysis of subgroups.
| Targeted NGS
NGS was carried out in genomic DNA samples isolated from patient blood samples with the NucleoSpin Blood kit according to the manufacturer's protocol (Macherey-Nagel, Germany). DNA quantification occurred with a Qubit 3 fluorometer using appropriate Qubit dsDNA reagents (Thermo Fisher Scientific, Invitrogen).
NGS was performed with a panel-based approach using the Illumina TruSight Cardio Sequencing Kit (Illumina). 6 With this approach, exonic regions of 174 cardiovascular disease genes specifically implicated in structural heart disease and arrhythmias were sequenced (https://support.illumina.com/sequencing/sequencing_ kits/trusight-cardio-sequencing-kit.html). Library preparation and enrichment was performed according to the manufacturer's protocol. Quantification of DNA libraries was performed with a Bioanalyzer 2100 using the high sensitivity DNA kit or DNA 1000 kit (Agilent Technologies). Patient DNA libraries were sequenced on a NextSeq 500 platform with mid output cartridge v2 with paired end sequencing (150 cycles) and dual indexing. Sanger sequencing was applied to validate variants detected by NGS in index patients and in family members for segregation analysis. Sanger sequencing was performed according to standard laboratory protocols. 7 The primer for genomic amplification of cardiac troponin I (TNNI3) polymerase chain reaction (PCR) products and Sanger sequencing is available in Table S1.
| Alignment of raw data and variant calling
The libraries were demultiplexed using bcl2fastq v2.17.1.14. The reads were then aligned using BWA-MEM v0.7.15 8 
| Bioinformatic evaluation and variant classification
The called variants were evaluated with Variant Studio (Illumina) for their minor allele frequency (<0.001) and mutation specification. We used Genome Aggregation Database (gnomAD) as genetic reference database for unaffected individuals (http://gnomad. broadinstitute.org/). 12 We evaluated 89 CMP disease genes that have been ascertained in a series of patients, preferably including family segregation data; CMP genes suggested from single case reports were excluded (Table S2) 14 using the recommended frequency threshold in CMPs of <0.0001. 15 For the purpose of this study, variant classification was reconfirmed by the classification on the National Center for Biotechnology (NCBI) database, ClinVar. 16 The most recent variant classification was used in the final analysis (https://www.ncbi.nlm.nih.gov/clinvar/). 17 For functional classification, the 89 genes evaluated in this study were arranged into functional groups (Table S2 ). 18 
| Protein and mRNA expression analysis
Age-matched human ventricular biopsies obtained at time of cardiac surgery (age range 5 months to 2.5 years) were subjected to protein and total RNA isolation after liquid nitrogen treatment and mechanical crashing. Powdered heart tissue was subjected to RNA isolation with Trizol reagent (Invitrogen, Carlsbad, CA) and protein lysates were obtained after incubation with RIPA buffer. Protein samples were analyzed by Western blot after sodium dodecylsulfate polyacrylamide gel electrophoresis and transfer onto polyvinylidene difluoride membrane For mRNA analysis, total RNA was isolated according to standard protocols and transcribed into cDNA with SuperscriptII (Invitrogen).
Quantitative PCR (qPCR) was performed on a Taqman 7500 (Applied Biosystems) using GAPDH as endogenous control. The relative mRNA level was calculated according to the ΔΔCT method. The primers used for qPCR are listed in Table S1. 3 | RESULTS Table 1 . Our pediatric CMP cohort was composed of patients with DCM (n = 34), HCM (n = 23), LVNC (n = 14), RCM (n = 7), and ARVC (n = 2) ( Figure 1A) . The age at diagnosis was <10 years in 63 patients (79%) and <1 year in 34 patients (43%). Of note, the age of diagnosis did not affect the relative CMP subtype frequency ( Figure 1A -C). Family members of 61 index patients (77%) underwent clinical evaluation. In 27 of these families, at least one additional affected family member was identified resulting in a 44% positive yield of family screening (- Table S3 ). The largest group was composed of DCM patients (43%) of which 50% underwent HTX. In addition, the DCM group had the highest rate of implanted ventricular assist device systems (47%), extracorporeal membrane oxygenation systems (15%), and death (6%). Within the whole cohort, one-third of patients (n = 26; 33%) already had a HTX at the time of enrollment or underwent HTX during the study period ( Figure 1D ).
| Patient characteristics
| Spectrum of detected rare variants in pediatric primary CMP
To identify a potential genetic defect, we screened all index patients with a panel-based NGS approach detecting genetic variants in 89 CMP-associated genes. In 46 of these 89 genes, we identified at least one rare variant. In total, 126 detected variants were classified as pathogenic (n = 17, 14%), probably pathogenic (n = 15, 12%), or VUS (n = 94, 74%) ( Table 2 ). Forty-two percentage (53/126) of all variants were novel and not annotated in disease reference databases; novel variants were mostly classified as VUS (42/53). One hundred three Missense variants were found in >80% of cases (103/126) and 37 of them were novel (37/103). In addition, 9 indel/frameshift, 3 stop gain, and 11 splice site rare variants were detected. From 75/126 rare variants, for which inheritance was tested in the parents, 7 (10%) arose de novo and 5/7 were classified as pathogenic and 2/7 were probably pathogenic. A detailed summary of all VOI is supplied in 
| TTN variants
VOI inducing truncations of the TTN protein (n = 4, 3% of all VOI)
were rarely found and occurred in three RCM as well as in one DCM patient, two probably pathogenic, and two VUS (Table S5 ). In RCM patients, three TTN splice-site variants were identified in three individuals, respectively, two VUS and one probably pathogenic ( Figure 2E ).
| Homozygous/compound heterozygous VOI
The vast majority of detected VOI were heterozygous, nevertheless;
we observed two homozygous (NEXN, TNNI3), and two compound heterozygous (DSC2, MYBPC3) VOI. In one case, we identified compound heterozygous mutation of MYBPC3 p.S858R with complete deletion of the MYBPC3 gene on the second allele. 19 T A B L E 2 Genetic variants of 80 index patients with pediatric cardiomyopathy 
| Hemizygous VOIs
Four hemizygous dystrophin (DMD), 1 four and a half LIM domains 1 (FHL1), and two tafazzin (TAZ) variants (Table S5) were also observed.
| VOI in HTX
Within this pediatric CMP cohort, one-third of patients (n = 26), mainly DCM and RCM, underwent HTX ( Figure 1D ). HTX patients most frequently carried variants in DSP (4 VUS), DMD (3 VUS), PRDM16 (3 VUS), and TTN (2 probably pathogenic, 1 VUS). Of note, three TTN splice or truncating variants were found in RCM as well as in DCM patients with HTX (Table S4 ). Fourteen HTX CMP patients exhibited ≥2 VOI, six patients had one VOI, and no VOI was identified in six patients.
| Homozygous loss of TNNI3 protein is compensated by upregulation of fetal TNNI1
Within the pediatric CMP cohort, VOI were most frequently detected in MYH7, MYBPC3, TNNI3, and DSP (Figure 2A ) Table S6 ). The TNNI3 protein is composed of a cardiac specific region, the IT arm region, and the flexible C-terminal tail ( Figure 4A ). 20 All heterozygous TNNI3 missense variants detected in this study cluster in exon 8 ( Figure 4B ). To further explore the molecular consequences of the truncating TNNI3 variants (c.240delG, p.Arg69Alafs*8; c.24+2T>A; c.624dupT, p.Glu209*), we determined mRNA and protein levels in heart biopsies. The TNNI3 protein is absent in patients 1-II:1 and 2-II:3 (Figure 4C,D) . Of note, the protein level of TNNI1, the fetal TNNI variant, is markedly higher in patients 1-II:1 and 2-II:3. The TNNI3 mRNA level is markedly reduced in patient 1-II:1, suggesting degradation by non-sense mediated decay, or not different from controls in patient 2-II:3 ( Figure 4E ). Levels of the sarcomeric proteins TNNT2 and MYBPC3 were not significantly affected. The TNNI3 protein level in a heart biopsy of patient 3-II:1 (p.E209*) was normal ( Figure S6A-C) . In contrast, the TNNI3 and TNNI1 transcript levels were higher in heart tissue of patient 3-II:1.
| DISCUSSION
In this study, we report the genetic basis of a cohort of 80 pediatric patients with pediatric primary CMP referred to a tertiary center. VOI were most frequently detected in the MYH7, MYBPC3, TNNI3, and DSP genes. TNNI3 is the third most important disease gene in this cohort and complete loss of myocardial TNNI3 was associated with severe CMP and a compensatory increase in TNNI1.
Our study serves to assess the impact of genetic testing for counseling and management of pediatric primary CMP patients, and it shows wide genetic heterogeneity, depending on the stringency of phenotypes included in the cohort. 2 The strength of this pediatric study is that it included only patients with primary CMP.
| Spectrum of genetic variants in pediatric primary CMP
In the entire cohort, we mainly identified patients with DCM and HCM, which is consistent with the established incidence of pediatric CMP. 5 Less frequently, we detected patients with LVNC and RCM.
F I G U R E 3 Families with CMP and mutation of TNNI3. A-F, Pedigrees of all families with rare genetic TNNI3 variants. Open symbols depict unaffected individuals and filled symbols affected family members. The phenotype is indicated for each pedigree. The TNNI3 genotype is presented for each pedigree, with the mutated allele marked as mut and the reference allele as wt. Individuals without genotype were not available for genetic testing. CMP, cardiomyopathy
Over all CMP subtypes, genetic variants were most frequently detected in sarcomeric genes (MYH7, MYBPC3, TNNI3) followed by desmosomal (DSP) and z-disc genes (LDB3, MYPN). 
| Hypertrophic cardiomyopathy
| Dilated cardiomyopathy
The spectrum of contributing genes differs among the age groups, most prominently, when comparing the infant group with the pediatric and adult groups. 22 
| Restrictive cardiomyopathy
A substantial proportion of pediatric RCM is caused by mutation of sarcomere genes. 23 In adults, genetic analysis of RCM is limited to individual consanguineous families and case reports. 24 
| Left ventricular non-compaction
Targeted NGS approaches revealed a wide spectrum of genetic variations and a high incidence of pathogenic variants in pediatric LVNC patients, mostly sarcomere gene variants. 25, 26 In adult cohorts, sarcomeric genes are the major disease genes for HCM (>70%), 27 DCM (14%, 35%, or 37%), 22, 28, 29 and LVNC (26% or 29%). 30, 31 In all CMP subgroups, patients carried most frequently VOI in sarcomere genes suggesting them as major contributor in pediatric CMP as previously shown in meta-analyses for adult-onset CMP. 32, 33 A detailed genotype-phenotype correlation was not intended in this study of index-patients due to the composition and small size of the This suggests a link of TTN truncation with pediatric RCM, potentially in combination with a more complex genetic alteration, and a critical importance of both TTN alleles for postnatal development. 24 In line with our observations, other studies showed that in children with DCM, the frequency of truncating TTN variants is much lower compared to adults. 22,34
| Segregation analysis
In 77% of families, we tested the variant inheritance and clinical status in first degree members. This approach allowed us to identify seven de novo variants (10%). This is a lower ratio of de novo variants than previously reported. 2 [36] [37] [38] Here, we showed absence of the TNNI3 protein in heart tissue of patients with homozygous TNNI3 mutation. Moreover, we suggest impaired TNNI isoform switching in the postnatal heart indicated by increased TNNI1 (fetal isoform) protein and mRNA levels in both patients. The switch from fetal TNNI1 to adult TNNI3 monitors cardiomyocyte maturation in mammalian heart tissue and in humaninduced pluripotent stem cell-derived cardiomyocytes. 39, 40 More importantly, TNNI switching critically determines Ca 2+ sensitivity, resistance to hypoxia/acidosis, and responsiveness to adrenergic stimulation of the contractile system. 41 Thus, defective TNNI1 to TNNI3 switching upon CMP associated TNNI3 mutation may prevent adequate adaptation to postnatal heart physiology.
| Pediatric CMP: Implications for genetic testing?
It is a matter of ongoing debate whether whole genome sequencing (WGS) or whole exome sequencing (WES) in CMP would be necessary to provide more insight into the genetic disease mechanisms. 42 The incremental yield of clinically actionable variants by WGS is limited by a paucity of genetic and functional evidence. 43 In a study by Herkert et al, combining copy number variant analysis with stepwise triobased WES yielded a diagnosis in more than 50% of pediatric DCM patients. 44 They identified patients with familial and non-familial DCM or a mixed cardiac phenotype with age at onset of CMP <18 years. These included patients with extracardiac features or possible myocarditis. Other recent studies lead to the identification of pathogenic variants in 26% to 39% of pediatric patients. 1, 2 Our study suggests genetic testing for sarcomere gene variants in severely affected children as early as possible to support clinical decision making. Altogether, these studies support the use of genetic testing in clinical practice by NGS, to improve risk stratification for clinically affected patients in selected CMP, such as pediatric CMP. 45 In summary, with an NGS panel-based approach, we identified the genetic cause in 38% of pediatric patients with primary CMP. Most frequently, we detected pathogenic or probably pathogenic missense variants in sarcomere genes such as MYH7, MYBPC3, and TNNI3.
Homozygous deactivation of TNNI3 leads to severe CMP in pediatric patients and compensatory expression of TNNI1. We propose that this study advances the general genetic understanding of pediatric primary CMP and highlights certain genetic defects with severe clinical courses.
